Contribute Try STAT+ Today

A large percentage of drug makers, universities, and hospitals continue to fail to publicly post clinical trials results, according to new data released by European officials, who took the opportunity to issue a reminder that the information is required in the interest of improving public health.

As of April, results were available for nearly one-third of completed clinical trials that were registered in the European Union clinical trials database, also known as EudraCT. Specifically, of almost 27,100 trials that were completed, results should have been posted for more than 18,400 of them, but results were available for only approximately 5,800 trials.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.